Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Felix, S.B.
Right arrow Articles by Baumann, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Felix, S.B.
Right arrow Articles by Baumann, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy

S.B. Felix*,1, A. Staudt1 and G. Baumann2

a Department of Internal Medicine B, Ernst-Moritz-Arndt, Universität, Greifswald, Germany
b Department of Internal Medicine I, Charité University Hospital, Humboldt University, Berlin, Germany

* Correspondence: Stephan B. Felix, MD, Klinik für Innere Medizin B, Medizinische Fakultät, Ernst-Moritz-Arndt-Universität, Loefflerstar. 23a, D-17487 Greifswald, Germany.

Abstract

Dilated cardiomyopathy (DCM) is a myocardial disease characterized by progressive depression of myocardial contractile function, and by ventricular dilatation. Abnormalities of the cellular and humoral immune system are present in a subset of patients with myocarditis and DCM. A number of various cardiac autoantibodies against cardiac cellular proteins have been identified in patients with myocarditis and DCM. Recent clinical studies showed that removal of antibodies by immunoadsorption improves cardiac function of patients with DCM indicating that activation of the humoral immune system may play a functional role in DCM.

Key Words: Dilated cardiomyopathy • humoral immune system • antibodies • immunoadsorption

References

  1. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841–842[ISI][Medline]
  2. Feldman AM, McNamara DM. Myocarditis. N Engl J Med. 2000;343:1388–1398[Free Full Text]
  3. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation. 2001;104:1076–1082[Free Full Text]
  4. Kühl U, Noutsias M, Schultheiss HP. Immunohistochemistry in dilated cardiomyopathy. Eur Heart J. 1995;16(suppl O):100–106
  5. Wojnicz R, Nowalany-Kozielska E, Wodniecki J, et al. Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Eur Heart J. 1998;19:1564–1572[Abstract/Free Full Text]
  6. Noutsias M, Seeberg B, Schultheiss HP, Kühl U. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation. 1999;99:2124–2131[ISI][Medline]
  7. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T-cell mediated disease. J Immunol. 1991;147:2141–2147[Abstract]
  8. Klappacher G, Mundigler G, Papousek A, et al. Elevated circulating levels of beta-2 microglobulin in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;71:119–122[CrossRef][ISI][Medline]
  9. Limas CJ, Goldenberg IF, Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies. Circulation. 1995;91:631–634[ISI][Medline]
  10. Schulze K, Becker BF, Schauer R, Schultheiss HP. Antibodies to ADP-ATP carrier — an autoantigen in myocarditis and dilated cardiomyopathy — impair cardiac function. Circulation. 1990;81:959–969[ISI][Medline]
  11. Caforio AL, Grazzini M, Mann JM, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85:1734–1742[ISI][Medline]
  12. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res. 1989;64:97–103[Abstract]
  13. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation. 1994;89:2760–2767[ISI][Medline]
  14. Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1993;91:1964–1968
  15. Fu ML, Schulze W, Wallukat G, Hjalmarson A, Hoebeke J. A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Clin Immunol Immunopathol. 1996;78:203–207[CrossRef][ISI][Medline]
  16. Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol. 2002;39:646[Abstract/Free Full Text]
  17. Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol. 1997;29:641–655[CrossRef][ISI][Medline]
  18. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–241[Abstract]
  19. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561–566[Abstract/Free Full Text]
  20. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92:1479–1486[ISI][Medline]
  21. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–711[ISI][Medline]
  22. Aukrust P, Damas JK, Gullestad L, Froland SS. Chemokines in myocardial failure — pathogenic importance and potential therapeutic targets. Clin Exp Immunol. 2001;124:343–345[CrossRef][ISI][Medline]
  23. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Cardiac Failure. 1996;2:243–249[CrossRef][Medline]
  24. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1998;30:215–223[CrossRef][ISI][Medline]
  25. Bozkurt B, Kribbs S, Clubb FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–1391[ISI][Medline]
  26. Kubota T, McTierman CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-{alpha}. Circ Res. 1997;81:627–635[Abstract/Free Full Text]
  27. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287:628–640[Abstract/Free Full Text]
  28. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999;99:3224–3226[ISI][Medline]
  29. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (enbrel) in patients with advanced heart failure. Circulation. 2001;103:1044–1047[ISI][Medline]
  30. Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: CAPRICON, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001. Eur J Heart Fail. 2001;3:381–387[CrossRef][ISI][Medline]
  31. Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321:1061–1068[Abstract]
  32. Mason JW, O'Connel JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269–275[Abstract/Free Full Text]
  33. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39–45[Abstract/Free Full Text]
  34. Bowles NE, Richardson PJ, Olsen EG, Archard LC. Detection of coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1986;1:1120–1123[ISI][Medline]
  35. Kandolf R, Ameis D, Kirschner P, Canu A, Hofschneider PH. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA. 1987. p. 6272–6276
  36. Jin O, Sole MJ, Butany JW, et al. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation. 1990;82:8–16[ISI][Medline]
  37. Pauschinger M, Bowles NE, Fuentes-Garcia FJ, et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation. 1999;99:1348–1354[ISI][Medline]
  38. Maisch B, Hufnagel G, Schönian U, Hengstenberg C. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J. 1995;16(suppl O):173–175
  39. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107–116[ISI][Medline]
  40. Godeau B, Lesage S, Divine M, Wirquin V, Farcet J, Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood. 1993;82:1415–1421[Abstract/Free Full Text]
  41. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med. 1986;146:1365–1368[Abstract]
  42. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220–225[ISI][Medline]
  43. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–2259[ISI][Medline]
  44. Dörffel WV, Felix SB, Wallukat G, et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation. 1997;95:1994–1997[ISI][Medline]
  45. Felix SB, Staudt A, Dörffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000;35:1590–1598[Abstract/Free Full Text]
  46. Müller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101:385–391[ISI][Medline]
  47. Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001;103:2681–2686[ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Felix, S.B.
Right arrow Articles by Baumann, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Felix, S.B.
Right arrow Articles by Baumann, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?